{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atomoxetine+hydrochloride&page=6",
    "query": {
      "intervention": "atomoxetine hydrochloride",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 128,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atomoxetine+hydrochloride&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atomoxetine+hydrochloride&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T00:22:56.094Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00089869",
      "title": "A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-07-20",
      "last_synced_at": "2026-11-19T00:22:56.094Z",
      "location_count": 20,
      "location_summary": "Cerritos, California • Chula Vista, California • Garden Grove, California + 15 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089869"
    },
    {
      "nct_id": "NCT02191358",
      "title": "YouScript IMPACT Registry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adverse Drug Events",
        "Adverse Drug Reactions",
        "Drug Interaction Potentiation",
        "Drug Metabolism, Poor, CYP2D6-RELATED",
        "Drug Metabolism, Poor, CYP2C19-RELATED",
        "Cytochrome P450 Enzyme Deficiency",
        "Cytochrome P450 CYP2D6 Enzyme Deficiency",
        "Cytochrome P450 CYP2C9 Enzyme Deficiency",
        "Cytochrome P450 CYP2C19 Enzyme Deficiency",
        "Cytochrome P450 CYP3A Enzyme Deficiency",
        "Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant",
        "Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant",
        "Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Genelex Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2014-10",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2017-03-01",
      "last_synced_at": "2026-11-19T00:22:56.094Z",
      "location_count": 7,
      "location_summary": "Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Fall River",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02191358"
    },
    {
      "nct_id": "NCT01399827",
      "title": "Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder (ADHD)",
        "Deficient Emotional Self-Regulation (DESR)"
      ],
      "interventions": [
        {
          "name": "ADHD Medication",
          "type": "DRUG"
        },
        {
          "name": "Omega-3 Fatty Acids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 2,
      "start_date": "2012-02",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2018-10-23",
      "last_synced_at": "2026-11-19T00:22:56.094Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01399827"
    },
    {
      "nct_id": "NCT00142961",
      "title": "Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity",
        "Marijuana Abuse"
      ],
      "interventions": [
        {
          "name": "Atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "14 Years to 21 Years"
      },
      "enrollment_count": 2,
      "start_date": "2005-10",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2019-04-23",
      "last_synced_at": "2026-11-19T00:22:56.094Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00142961"
    },
    {
      "nct_id": "NCT06899178",
      "title": "Atomoxetine in Melanocortin Obesity Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanocortin Obesity Syndrome",
        "MCOS"
      ],
      "interventions": [
        {
          "name": "Atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-09-01",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-11-19T00:22:56.094Z",
      "location_count": 3,
      "location_summary": "New York, New York • Columbus, Ohio • Nashville, Tennessee",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06899178"
    },
    {
      "nct_id": "NCT01498549",
      "title": "Cognitive Effects of Atomoxetine in Humans: Genetic Moderators",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Addiction"
      ],
      "interventions": [
        {
          "name": "Atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "Sugar Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 35,
      "start_date": "2011-12",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2017-07-11",
      "last_synced_at": "2026-11-19T00:22:56.094Z",
      "location_count": 1,
      "location_summary": "West Haven, Connecticut",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01498549"
    },
    {
      "nct_id": "NCT00634439",
      "title": "Safety Study of Atomoxetine and Cerebrovascular Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cerebrovascular Accident",
        "Transient Ischemic Attack",
        "ADHD"
      ],
      "interventions": [
        {
          "name": "atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "Stimulants",
          "type": "DRUG"
        },
        {
          "name": "No intervention (general population)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72000,
      "start_date": "2008-01",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2009-09-15",
      "last_synced_at": "2026-11-19T00:22:56.094Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634439"
    },
    {
      "nct_id": "NCT00918567",
      "title": "Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "Behavior Modification Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 56,
      "start_date": "2007-01",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2020-10-20",
      "last_synced_at": "2026-11-19T00:22:56.094Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00918567"
    },
    {
      "nct_id": "NCT00190736",
      "title": "Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Atomoxetine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "54 Years",
        "sex": "ALL",
        "summary": "18 Years to 54 Years"
      },
      "enrollment_count": 440,
      "start_date": "2004-09",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2007-11-06",
      "last_synced_at": "2026-11-19T00:22:56.094Z",
      "location_count": 19,
      "location_summary": "Lafayette, California • Spring Valley, California • Farmington, Connecticut + 16 more",
      "locations": [
        {
          "city": "Lafayette",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00190736"
    },
    {
      "nct_id": "NCT00880217",
      "title": "A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Atomoxetine 80 mg/d",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "OROS methylphenidate HCl 54 mg/d",
          "type": "DRUG"
        },
        {
          "name": "JNJ-31001074 3 mg/d",
          "type": "DRUG"
        },
        {
          "name": "JNJ-31001074 1 mg/d",
          "type": "DRUG"
        },
        {
          "name": "JNJ-31001074 10 mg/d",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 430,
      "start_date": "2009-05",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2013-03-04",
      "last_synced_at": "2026-11-19T00:22:56.094Z",
      "location_count": 35,
      "location_summary": "Little Rock, Arkansas • Lafayette, California • Los Alamitos, California + 32 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lafayette",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Wildomar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00880217"
    }
  ]
}